Kasuistik: Management eines limbalen Carcinoma in situ der Bindehaut

Translated title of the contribution: Case report: Management of a Carcinoma in situ (CIS) of the limbal conjunctiva

Max Brinkmann, Salvatore Grisanti, Mariella Fleischer, Armin Mohi*

*Corresponding author for this work

Abstract

The carcinoma in situ (CIS) of the conjunctiva is one of the most common forms of ocular surface squamous neoplasia (OSSN). Besides classical surgical excision, treatment options involve application of adjuvant chemotherapeutics or as monotherapy. We treated a patient with limbal CIS exclusively conservatively by applying mitomycin C (MMC) eyedrops. There were no signs of dysplasia or malignancy 3 months after the treatment and even after 12 months there were no clinical findings of recurrence. Surgical removal remains the primary treatment for OSSN. Nevertheless, for the past 15 years there has been a trend to consider adjuvant or primary topical chemotherapy as a treatment option, especially if removal of the lesion was incomplete. The potential side effects and the extensive infrastructural requirements should always be taken into consideration.

Translated title of the contributionCase report: Management of a Carcinoma in situ (CIS) of the limbal conjunctiva
Original languageGerman
JournalSpektrum der Augenheilkunde
ISSN0930-4282
DOIs
Publication statusAccepted/In press - 2020

Fingerprint

Dive into the research topics of 'Case report: Management of a Carcinoma in situ (CIS) of the limbal conjunctiva'. Together they form a unique fingerprint.

Cite this